Publicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (20)

2024

  1. Carbon-Based Nanostructures as Emerging Materials for Gene Delivery Applications

    Pharmaceutics, Vol. 16, Núm. 2

2023

  1. 3D Bioprinting for Musculoskeletal Applications

    3D Printing and Bioprinting for Pharmaceutical and Medical Applications (CRC Press), pp. 147-168

  2. Erratum: Nanodiamonds Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases (ACS Appl. Mater. Interfaces (2022) 14:11 (13665−13677) DOI: 10.1021/acsami.2c02182)

    ACS Applied Materials and Interfaces

  3. Long-term biophysical stability of nanodiamonds combined with lipid nanocarriers for non-viral gene delivery to the retina

    International Journal of Pharmaceutics, Vol. 639

2022

  1. Multicomponent Synthesis of Unsaturated γ-Lactam Derivatives. Applications as Antiproliferative Agents through the Bioisosterism Approach: Carbonyl vs. Phosphoryl Group

    Pharmaceuticals, Vol. 15, Núm. 5

  2. Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases

    ACS Applied Materials and Interfaces, Vol. 14, Núm. 11, pp. 13665-13677

  3. Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging

    Pharmacological reviews, Vol. 74, Núm. 2, pp. 439-461

2021

  1. A multicomponent protocol for the synthesis of highly functionalized γ-lactam derivatives and their applications as antiproliferative agents

    Pharmaceuticals, Vol. 14, Núm. 8

  2. Correlation between biophysical properties of niosomes elaborated with chloroquine and different tensioactives and their transfection efficiency

    Pharmaceutics, Vol. 13, Núm. 11

  3. Current insights into 3D bioprinting: An advanced approach for eye tissue regeneration

    Pharmaceutics, Vol. 13, Núm. 3, pp. 1-28

  4. How far are non‐viral vectors to come of age and reach clinical translation in gene therapy?

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

  5. Sphingolipid extracts enhance gene delivery of cationic lipid vesicles into retina and brain

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 169, pp. 103-112

2020

  1. Brain Angiogenesis Induced by Nonviral Gene Therapy with Potential Therapeutic Benefits for Central Nervous System Diseases

    Molecular pharmaceutics, Vol. 17, Núm. 6, pp. 1848-1858

  2. Niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues

    Pharmaceutics, Vol. 12, Núm. 3

  3. Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

    International Journal of Pharmaceutics, Vol. 588

2019

  1. Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 308-318

2018

  1. Hyaluronic acid hydrogel scaffolds loaded with cationic niosomes for efficient non-viral gene delivery

    RSC Advances, Vol. 8, Núm. 56, pp. 31934-31942

  2. Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration

    International Journal of Pharmaceutics, Vol. 550, Núm. 1-2, pp. 388-397

2017

  1. Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis

    Drug Development and Industrial Pharmacy, Vol. 43, Núm. 7, pp. 1071-1081

  2. Non-viral vectors based on magnetoplexes, lipoplexes and polyplexes for VEGF gene delivery into central nervous system cells

    International Journal of Pharmaceutics, Vol. 521, Núm. 1-2, pp. 130-140